Impact of endothelin blockade on acute exercise-induced changes in blood flow and endothelial function in type 2 diabetes mellitus

Experimental Physiology

Volumn 99, Issue 9, 2014, Pages 1253-1264

  Schreuder, Tim H A ^a   van Lotringen, Jaap H ^a   Hopman, Maria T E ^a   Thijssen, Dick H J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; PLACEBO; ENDOTHELIN RECEPTOR ANTAGONIST; SULFONAMIDE;

ADULT; ARTICLE; BLOOD FLOW; BLOOD VESSEL PARAMETERS; BLOOD VESSEL TONE; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; EXERCISE; HAND GRIP; HUMAN; MALE; MAXIMAL VOLUNTARY CONTRACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SHEAR RATE; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION; AGED; BLOOD; BLOOD FLOW VELOCITY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HAND STRENGTH; METABOLISM; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

AGED; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIUM, VASCULAR; EXERCISE; HAND STRENGTH; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; REGIONAL BLOOD FLOW; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 84908351752     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2013.077297     Document Type: Article

References (41)

1. Bauer TA, Reusch JE, Levi M & Regensteiner JG (2007). Skeletal muscle deoxygenation after the onset of moderate exercise suggests slowed microvascular blood flow kinetics in type 2 diabetes. Diabetes Care 30, 2880-2885.
2. Brunnekreef JJ, Benda NM, Schreuder TH, Hopman MT & Thijssen DH (2002). Impaired endothelial function and blood flow in repetitive strain injury. Int J Sports Med 33, 835-841.
3. Cardillo C, Campia U, Bryant MB & Panza JA (2002). Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106, 1783-1787.
4. Clark CM Jr (2000). Combating sloth as well as gluttony: the role of physical fitness in mortality among men with type 2 diabetes. Ann Intern Med 132, 669-670.
5. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W (1994). Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270, 228-235.
6. de Groot PC, Bleeker MW & Hopman MT (2006). Magnitude and time course of arterial vascular adaptations to inactivity in humans. Exerc Sport Sci Rev 34, 65-71.
7. Green DJ, Maiorana A, O'Driscoll G & Taylor R (2004). Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol 561, 1-25.
8. Haffner SM (1998). Epidemiology of type 2 diabetes: risk factors. Diabetes Care 21 Suppl 3, C3-C6.
9. Harris RA, Padilla J, Hanlon KP, Rink LD & Wallace JP (2007). Reproducibility of the flow-mediated dilation response to acute exercise in overweight men. Ultrasound Med Biol 33, 1579-1585.
10. Harris RA, Padilla J, Hanlon KP, Rink LD & Wallace JP (2008). The flow-mediated dilation response to acute exercise in overweight active and inactive men. Obesity (Silver Spring) 16, 578-584.
11. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, (2013). http://www.idf.org/diabetesatlas
12. Johnson BD, Padilla J & Wallace JP (2012). The exercise dose affects oxidative stress and brachial artery flow-mediated dilation in trained men. Eur J Appl Physiol 112, 33-42.
13. Kalani M, Pernow J, Bragd J & Jörneskog G (2008). Improved peripheral perfusion during endothelin-A receptor blockade in patients with type 2 diabetes and critical limb ischemia. Diabetes Care 31, e56.
14. Kasimay O, Ergen N, Bilsel S, Kaçar O, Deyneli O, Gogas D, Akalin S, Yeğen BÇ & Kurtel H (2010). Diet-supported aerobic exercise reduces blood endothelin-1 and nitric oxide levels in individuals with impaired glucose tolerance. J Clin Lipidol 4, 427-434.
15. King H, Aubert RE & Herman WH (1998). Global burden of diabetes 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 21, 1414-1431.
16. Kingwell BA, Formosa M, Muhlmann M, Bradley SJ & McConell GK (2003). Type 2 diabetic individuals have impaired leg blood flow responses to exercise: role of endothelium-dependent vasodilation. Diabetes Care 26, 899-904.
17. Kirkby NS, Hadoke PWF, Bagnall AJ & Webb DJ (2008). The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153, 1105-1119.
18. Lalande S, Gusso S, Hofman PL & Baldi JC (2008). Reduced leg blood flow during submaximal exercise in type 2 diabetes. Med Sci Sports Exerc 40, 612-617.
19. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM & Burnett JC Jr (1991). Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325, 997-1001.
20. Maiorana A & O'Driscoll G (2001). The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 38, 860-866.
21. Maiorana A, O'Driscoll G, Goodman C, Taylor R & Green D (2002). Combined aerobic and resistance exercise improves glycemic control and fitness in type 2 diabetes. Diabetes Res Clin Pract 56, 115-123.
22. Marwick T, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, Philippides G, Rocchini A; Council on Clinical Cardiology, American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Nutrition, Physical Activity, and Metabolism; Interdisciplinary Council on Quality of Care and Outcomes Research (2009). Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119, 3244-3262.
23. Mather KJ, Lteif AA, Veeneman E, Fain R, Giger S, Perry K & Hutchins GD (2010). Role of endogenous ET-1 in the regulation of myocardial blood flow in lean and obese humans. Obesity (Silver Spring) 18, 63-70.
24. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO & Baron AD (2002). Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51, 3517-3523.
25. Mohler ER 3rd, Lech G, Supple GE, Wang H & Chance B (2006). Impaired exercise-induced blood volume in type 2 diabetes with or without peripheral arterial disease measured by continuous-wave near-infrared spectroscopy. Diabetes Care 29, 1856-1859.
26. Motte S, McEntee K & Naeije R (2006). Endothelin receptor antagonists. Pharmacol Ther 110, 386-414.
27. Pyörälä K, Laakso M & Uusitupa M (1987). Diabetis and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3, 463-524.
28. Rafnsson A, Böhm F, Settergren M, Gonon A, Brismar K & Pernow J (2012). The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 55, 600-607.
29. Settergren M, Pernow J, Brismar K, Jörneskog G & Kalani M (2008). Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. J Vasc Res 45, 295-302.
30. Timm M, Kaski JC & Dashwood MR (1995). Endothelin-like immunoreactivity in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 26 Suppl 3, S442-S444.
31. Tinken TM, Thijssen DH, Hopkins N, Black MA, Dawson EA, Minson CT, Newcomer SC, Laughlin MH, Cable NT & Green DJ (2009). Impact of shear rate modulation on vascular function in humans. Hypertension 54, 278-285.
32. Tinken TM, Thijssen DH, Hopkins N, Dawson EA, Cable NT & Green DJ (2010). Shear stress mediates endothelial adaptations to exercise training in humans. Hypertension 55, 312-318.
33. Tooke J (2000). Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 14, 197-200.
34. Tuttle JL, Nachreiner RD, Bhuller AS, Condict KW, Connors BA, Herring BP, Dalsing MC & Unthank JL (2001). Shear level influences resistance artery remodeling: wall dimensions, cell density, and eNOS expression. Am J Physiol Heart Circ Physiol 281, H1380-H1389.
35. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, Jonkman JH & Jones CR (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60, 124-137.
36. Wei M, Gibbons LW, Kampert JB, Nichaman MZ & Blair SN (2000). Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 132, 605-611.
37. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, Jones CR, Clozel M, Meier B & Luscher TF (1998). Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98, 2235-2240.
38. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA & Green D (2001). Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 91, 929-937.
39. Wray DW, Nishiyama SK, Donato AJ, Sander M, Wagner PD & Richardson RS (2007). Endothelin-1-mediated vasoconstriction at rest and during dynamic exercise in healthy humans. Am J Physiol Heart Circ Physiol 293, H2550-H2556.
40. Wricht CI, Kroner CI & Draijer R (2006). Non-invasive methods and stimuli for evaluating the skins's microcirculation. J Pharmacol Toxicol Methods 54, 1-25.
41. Zhu W, Zeng J, Yin J, Zhang F, Wu H, Yan S & Wang S (2010). Both flow-mediated vasodilation procedures and acute exercise improve endothelial function in obese young men. Eur J Appl Physiol 108, 727-732.